In contrast to selective targeting of the cytokine IL-17, combined targeting of the IL-23/IL-17 axis with ustekinumab, a monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23, is an effective treatment strategy in IBD [260]. Here, IL17A is linked to inflammatory bowel disease.